重症血友病Aまたは中等度から重症血友病Bの成人および10代の参加者におけるPF-06741086の有効性と安全性の研究

基本情報

NCT ID

NCT03938792

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

189

治験依頼者名

Pfizer

概要

Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to current methods of treatment for hemophilia A or B because it works differently than factor replacement products and will work in the presence of inhibitors. The potential for once weekly (QW) subcutaneous (SC) administration provides for treatment options in the absence of reliable vascular access, increased convenience and may enable better compliance. Combined, these qualities should result in a reduction of bleeding episodes.

対象疾患

介入

依頼者（Sponsor）

実施施設 (4)